Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rare blood disorder

- PMLiVE

Roche pays $220m for blood-testing company

Boosts diagnostics business with acquisition of Constitution Medical Investors

- PMLiVE

Novartis and Savient face NICE rejections

Jakavi and Krystexxa turned down for NHS use in England and Wales

Novartis building

Novartis’ omalizumab on track for filing in serious skin disease

Is active ingredient in asthma drug Xolair

- PMLiVE

Sandoz takes short route for biosimilar Enbrel approval

Novartis subsidiary initiates late-stage trial to support use in chronic plaque-type psoriasis

Novartis building

US FDA deems Novartis’ heart failure candidate a ‘breakthrough’

Serelaxin demonstrates ability to reduce shortness of breath and lower chance of dying

- PMLiVE

Novartis launches European advanced breast cancer campaign

Campaign launches with audio/visual installation

- PMLiVE

Elotuzumab on track for multiple myeloma

BMS and AbbVie present phase II results at European Haematology Association meeting

Novartis building

Jakavi shows long-term survival benefit in myelofibrosis

Trial demonstrates Novartis’ blood cancer drug cut risk of death by half over three years

- PMLiVE

Alcon wins initial NICE backing for Jetrea in rare eye condition

Would be first alternative to surgery available to vitreomacular traction patients in England and Wales

- PMLiVE

Celgene’s Revlimid wins US lymphoma approval

FDA recommends extra indication for blockbuster cancer drug

- PMLiVE

GSK eyes first-line use for leukaemia drug Arzerra

Positive phase III trial results back regulatory filings for earlier use

- PMLiVE

Novartis wins third NICE recommendation for Lucentis

Gains final backing to treat NHS patients with macular oedema

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links